Qualiber, Inc. 
Company
Qualiber, Inc. is a nanomedicine company with the mission to deliver innovative treatments for cancer and other life threatening diseases. Utilizing nanotechnology it is creating medicines that have superior efficacy and safety profile. In addition, Qualiber is partnering with pharmaceutical/biotechnology companies to address delivery challenges of partner’s treatments.
The company has secured funding from the National Cancer Institute, UNC-CH, the North Carolina Biotechnology Center and pharmaceutical company partners. The company is seeking $500K first tranche of $5M Series A funding to progress lead cancer product, NanoGTP™ (Nanomedicine delivering Gemcitabine Tri-Phosphate) towards human clinical trials.
1st Product: NanoGTP™, demonstrated superior efficacy & safety in animal models of human cancer
Cancer (especially pancreatic and lung cancer) is a continuing leading cause of death and suffering in the US and the World. Though there are chemotherapeutic drugs on the market, most have limited effectiveness and cause serious side effects/toxicities. Qualiber is developing its first product NanoGTP for pancreatic and lung cancers. NanoGTP substantively improves the delivery of existing anticancer drug, gemcitabine, and enhances the potential for greater clinical benefit and expanded use. In preclinical animal models of human cancer NanoGTP has demonstrated superior efficacy and safety than gemcitabine. Company expects to complete scale-up manufacturing and preclinical toxicology studies by end-2013 followed by Investigational New Drug (IND) application filing to the FDA in 2014. The market for pancreatic cancer treatments is estimated to be $1.2Billion in 2015 and for lung cancer to be $9.5Billion in 2018.
Founders and Management Team
· Dr. Anil K. Goyal, President & CEO. Over 20 years of leadership experience at venture-backed and public biotechnology companies. Managed and led exits: Optherion’s diagnostics division sale and Serenex >$300M sale to Pfizer.
· Dr. Leaf Huang, CSO and Co-founder. Distinguished Professor and Chair, Division of Molecular Pharmaceutics, UNC-Chapel Hill. More than 30 years research experience and world-renowned in development of liposome based drug and gene-delivery systems. Co-founder of four other companies.
